In vitro studies reported that inhibition of Bcl-2/Bcl-xL, along with an antitumor agent that induces TRAIL pathway-mediated cell death give a strong synergistic anti-proliferative effect on pediatric, adult, proneural GBM and glioma stem-like cells [36]. The gene discussed is BCL2L1; the disease is glioblastoma.